The 17 references in paper , , , , А. Калемберг А., К. Давтян В., Г. Симонян Ю., В. Шатахцян С. (2016) “CОВРЕМЕННЫЕ СТРАТЕГИИ ПРОФИЛАКТИКИ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ У ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ” / spz:neicon:aterotromboz:y:2016:i:2:p:7-13

1
Wyndham CR. Atrial fibrillation: the most common arrhythmia. Tex Heart Inst J,2000, 27(3): 257-67.
(check this in PDF content)
2
Stewart S, Yart CL, Hole DJ, VcVurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Yeart,2001, 86: 516-521.
(check this in PDF content)
3
Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M et al. Apixaban in Compared with Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the ARISTOTLE Trial. Circulation, 2015, 132: 624-632.
(check this in PDF content)
4
Ezekowitz MD, Parise H, Nagarakanti R, Noack H, Brueckmann M, Clemens A et al. Comparison of dabigatran versus warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LYw trial. J Am Coll Cardiol, 2014, 63(12, Supplement): A325.
(check this in PDF content)
5
Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J, 2014, 35: 3377-3385.
(check this in PDF content)
6
Oldgren J, Wallentin L, Alexander JH, James S, Jonelid B, Steg G et al. Neworal anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and metaanalysis. Eur Heart J, 2013, 34: 1670-1680.
(check this in PDF content)
7
Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost, 2014, 111: 789-797.
(check this in PDF content)
8
Bronnum Nielsen P, Larsen TB, Gorst-Rasmussen A, Skjoth F, Rasmussen LH, Lip GY. Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a nationwide cohort study. Chest, 2015, 147: 1651-1658.
(check this in PDF content)
9
Vermeer SE, Algra A, Franke CL, Koudstaal PJ, Rinkel GJ. Long-term prognosis after recovery from primary intracerebral hemorrhage. Neurology, 2002, 59: 205-209.
(check this in PDF content)
10
Линчак Р.М., Компаниец О.Г., Недбайкин А.М., Комков Д.С., Юсова И.А Что думают и знают врачи об антитромботической терапии при фибрилляции предсердий? Кардиология, 2014, 10.
(check this in PDF content)
11
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. doi:10.1093/europace/ euv309. Published August 31, 2015.
(check this in PDF content)
12
Blackshear J, Odell J. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg, 1996, 61: 755-759.
(check this in PDF content)
13
Reddy VY, Sievert H, Halperin J et al. Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation: A Randomized Clinical Trial.JAMA, 2014, 312(19): 1988-1998. doi:10.1001/jama.2014.15192.
(check this in PDF content)
14
HRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. EuroIntervention 2014. 10-online publish-ahead-ofprint August 2014.
(check this in PDF content)
15
Boersma LVA, Schmidt B еt al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. European Heart Journal. doi:10.1093/eurheartj/ehv730.
(check this in PDF content)
16
Holmes DR, Kar S, Price MJ et al. Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: The PREVAIL Trial.J Am Coll Cardiol, 2014, 64(1): 1-12. doi:10.1016/j.jacc. 2014.04.029.
(check this in PDF content)
17
Sandeep Panikker, Joanne Lord, et al. Outcomes and costs of left atrial appendage closure from randomized controlled trial and real world experience relative to oral anticoagulation. European Heart Journal, doi:10.1093/eurheartj/ehw048.
(check this in PDF content)